KING OF PRUSSIA, Pa., Nov. 2, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug ...
The first sickle cell disease patient has been enrolled in a Phase 1b trial testing iadademstat, Oryzon Genomics' ...
A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback